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Biliary fibrosis and resultant cirrhosis are among the most common outcomes of chronic liver diseases.
Currently, liver transplantation remains the only effective treatment. In seeking alternative therapeutic ap-
proaches, we focused on the potential use of the human amniotic membrane (AM). Indeed, AM has gained
increasing importance for its antiscarring, anti-inflammatory, and wound-healing properties, as well as for
the multipotent differentiation ability and immunomodulatory features of AM-derived cells. Intriguingly, we
have recently demonstrated that placenta-derived cells reduce lung fibrosis in bleomycin-treated mice, and
that AM patches reduce postischemic cardiac injury in rats. Hence, we have now investigated the effects of
human AM on biliary fibrosis induced in rats through the bile duct ligation (BDL) procedure. A fragment
of human AM was applied onto the liver surface after BDL and the effects on fibrosis establishment and
progression were evaluated at different time points in comparison with fibrosis progression in control BDL
rats. The degree of liver fibrosis was first assessed by the semiquantitative Knodell scoring system and,
thereafter, by digital image morphometric analysis to quantify the area occupied by ductular reaction, acti-
vated myofibroblasts, and collagen deposition. We demonstrated a significant reduction in the severity of
BDL-induced fibrosis in AM-treated rats. Indeed, while fibrosis progressed rapidly in control BDL rats,
leading to cirrhosis within 6 weeks, AM-treated rats showed confined fibrosis at the portal/periportal area
with no signs of cirrhosis, and a reduction in collagen deposition to about 50% of levels observed in control
BDL rats. In addition, the AM was able to significantly slow the gradual progression of the ductular reaction
and reduce, at all time points, the area occupied by activated myofibroblasts. These findings suggest that
human AM, when applied as a patch onto the liver surface, might inhibit fibrosis progression in BDL-injured
livers, and could protect against hepatic damage associated with fibrotic degeneration.
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INTRODUCTION of developing irreversible liver failure or hepatocellular
carcinoma in later life (46).
Despite decades of research that has led to substantialLiver fibrosis is a common outcome of a variety of
chronic liver diseases following different insults, such advances in understanding the molecular mechanisms of
this disease’s progression, hepatic cirrhosis remains aas viral infection, alcoholism, chemical toxicity, or met-
abolic and biliary disorders (23,38). Following repeated pathology that is difficult to treat in an effective manner
unless orthotopic liver transplantation is performedinjuries, the liver undergoes fibrotic remodeling charac-
terized by an excessive accumulation of extracellular (31,43). However, this approach presents with several
limitations of its own, such as: i) scarce availability ofmatrix (ECM) in the liver parenchyma that distorts the
normal hepatic architecture, with the formation of scar donor livers, ii) the need to commit transplant patients
to life-long toxic immunosuppression; iii) the fact thattissue encapsulating the area of injury (11). Progressive
fibrosis could end in the advanced stage known as cir- many patients may be unsuitable for transplantation
(35). Therefore, alternative therapies are urgently needed.rhosis, characterized by fibrotic septa and rings of scar
tissue that surround regenerative nodules of liver paren- More recently, hepatocyte transplantation has become
a promising therapeutic tool for a variety of liver dis-chyma (11,38). Patients with cirrhosis have a high risk
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eases (19,20,51). However, this approach is also cur- (4) and also to differentiate toward the hepatogenic lin-
eage in vitro and in vivo (34,52,54).rently limited by different factors, such as the restricted
availability of liver for hepatocyte isolation, the poor On the other hand, several studies testify that trans-
plantation of an intact AM fragment exerts anti-infam-quality of the cells obtained after the isolation proce-
dure, the modest level of engraftment achieved in the matory and antiscarring effects reviewed in Gomes et al.
(22), Fernandes et al. (18), and Dua et al. (15). In addi-host liver after transplantation, and low cell viability,
which is one of the reasons that long-term beneficial tion, more recently, preclinical studies have shown that,
likely by means of paracrine mechanisms, transplanta-effects are often not observed following hepatocyte
transplantation (19,20,32). tion of xenogenic and allogenenic placenta-derived cells
reduces lung fibrosis in bleomycin-treated mice (9),The use of stem or progenitor cell transplantation is
emerging as a potential alternative to hepatocyte trans- while application of a human AM patch onto ischemic
rat hearts results in improved cardiac function (8). Takenplantation for the treatment of liver disorders (36,44),
and several potential sources have been identified for together, these findings suggest that transplantation of
AM-derived cells and/or AM itself could be a novelthe isolation of these cells (28). For the treatment of
liver fibrosis, this approach has been performed mainly therapeutic strategy to treat hepatic diseases.
The purpose of this study was to evaluate the effectsusing bone marrow-derived mesenchymal stromal cells
(MSCs), although the results that have been obtained of human AM patches on the establishment and progres-
sion of biliary-type liver fibrosis induced in rats throughso far are controversial (reduction vs. enhancement of
fibrosis), and open questions also remain regarding the the bile duct ligation (BDL) procedure.
mechanisms involved (1,11). At least two possible
MATERIALS AND METHODSmechanisms have been proposed for the potential thera-
Animals and Experimental Groupspeutic function on liver fibrosis exerted by MSCs: one
implies their ability to engraft into the liver and differen- All animal experiments were carried out in accor-
tiate towards the hepatogenic lineage, therefore partici- dance with current Italian and European regulations and
pating in the regeneration of the endogenous paren- laws on the Use and Care of Animals for research (DL.
chyma; the other possible mechanism, which seems the 116/27 January 1992). Sixty female Wistar rats (Labora-
most likely, is related to the ability of MSCs to produce/ toire Elevage Janvier, France), weighing 220–250 g,
activate paracrine mediators, such as IL-10, TNF-α, and were housed at controlled temperature (22 ± 2°C) with
HGF, which lead to reduction of fibrosis [for a review daily exposure to a 12:12 light/dark cycle and allowed
see Dai et al. (11) and Henderson and Forbes (23)]. unlimited access to chow and water. Before any experi-
Many issues remain to be addressed before stem cell mental intervention, the rats were randomly divided into
therapy can be considered as a viable clinical strategy two experimental groups of 30 rats each, as follows:
for such a liver disease, and among these is the need to BDL group—rats subjected to the BDL procedure and
identify a source of stem cells that is safe, does not pose euthanized at 2 (n = 10), 4 (n = 10), and 6 weeks (n = 10)
any risk of tumor induction and/or risk of viral infection after ligation; BDL + AM group—rats subjected to the
(16), is easily accessible, provides a high cell yield, and BDL procedure and treated with human AM and euthan-
for which cell procurement does not provoke ethical de- ized at 2 (n = 10), 4 (n = 10), and 6 (n = 10) weeks after
bate (17,32). To this end, the human amniotic membrane ligation.
(AM) represents a prime candidate as a possible source
Human AM Collectionof stem/progenitor cells. Cells isolated from this mem-
brane have a stem cell phenotype: human amniotic epi- Human term placentas were obtained from caesarean
sections or spontaneous deliveries with maternal consentthelial cells (hAEC) express pluripotent stem cell mark-
ers and are able to differentiate in vitro toward tissues of according to the guidelines of the Ethical Committee of
the Catholic Hospital (CEIOC). Briefly, the human AMall three germ layers (33,37,53), while human amniotic
mesenchymal stromal cells (hAMSC), like MSCs of was manually separated from the chorionic membrane
and washed extensively in phosphate-buffered salineother origins, have the capacity to differentiate towards
cells of the mesodermal lineages, as well as toward tis- (PBS) (Sigma, St. Louis, MO, USA) containing 100 U/
ml penicillin and 100 µg/ml streptomycin (Lonza, Basel,sues of ectodermal and endodermal layers (39,49,53).
Several findings suggest that human AM-derived Switzerland). The AM was then cut into pieces of ade-
quate dimension (6 × 8 cm) that were stored separatelycells might be useful for restoring the functionality of
hepatic tissues that have been compromised by disease at room temperature, as reported by Hennerbichler et al.
(24), in 50-ml vials filled with serum-free and phenolor injury.
On one hand, there are data suggesting the potential red-free DMEM in sterile conditions, until application.
The AM fragments were used within 24 h. As pre-ability of human AM-derived cells to engraft in the liver
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viously reported, the number and viability of cells in the slides (Menzel-Glaser, Braunsch, Germany) for immu-
nohistochemical stainings.human AM fragments stored for 24 h were not signifi-
cantly reduced compared to those seen using fresh mem-
Liver Fibrosis Evaluationbrane (8).
The degree of liver fibrosis was examined semiquan-
titatively under a bright field Olympus microscope atRat Model of BDL-Induced Fibrosis
100× magnification by applying the Knodell fibrosisThe rats were anesthetized with 3% isoflurane. The
scoring as follows (7): level 0, indicating absence of fi-
abdomen was shaved and disinfected with 10% povi- brosis; level 1, fibrous portal expansion; level 3, bridg-done iodine and, after a midline abdominal incision, the ing fibrosis (portal–portal or portal–central vein link-
common bile duct was exposed and ligated by double
age); level 4, cirrhosis. The scoring was performedligatures with 4-0 suture silk (Johnson & Johnson Medi- blindly by a pathologist, who was not aware of the treat-
cal S.P.A. Rome, Italy). The first ligature was made be-
ments of the rats. The average of the score taken fromlow the junction of the hepatic ducts and the second 10 nonoverlapping random fields per section was usedligature was made above the entrance of the pancreatic
to generate a single score for each specimen.duct, as reported by Chen et al. (10). The common bile
duct was then sectioned between the ligatures. The ab- Immunohistochemistry
dominal incision was then closed in two layers with 4-0 Immunostainings for cytokeratin 19 (CK19) and α-
and 3-0 suture silk. Thus, animals had total, permanent
smooth muscle actin (α-SMA) were performed to iden-biliary obstruction.
tify bile ductular structures and activated myofibroblasts,In animals of the AM-treated group, immediately
respectively. Briefly, each section was immersed into
after BDL and before closing of the abdominal wall, an
the preheated target retrieval solution (W-CAP citrateAM fragment was gently placed onto the liver with its buffer pH 6.0) (BioOptica, Milano, Italy) and incubated
mesenchymal side in contact with the liver surface, in for 30 min at 98°C. This solution achieves, in just one
such way that the whole surface of the liver lobules was
step, deparaffinization and heat-induced epitope re-
covered. Holding its upper extremities using two for-
trieval. Endogenous peroxidase activity was blocked
ceps, the membrane was inserted under the liver and,
with 3% hydrogen peroxide for 10 min followed by
with gentle movements, it was then cranially shifted and
three washes in PBS containing 0.05% Tween 20
raised until it covered the surface of the median lobe. (Sigma). Sections were then incubated overnight in aThe inferior membrane extremities were also raised in humidity chamber at 4°C with primary mouse mono-
order to cover the remaining liver lobes and, finally, the
clonal antibodies against human α-SMA (Clone 1A4,
superior and the inferior membrane extremities were dilution 1:600, Dako Corporation, Denmark), which
attached to each other with a drop of methacrylate glue
cross-reacts with the rat antigen α-SMA (48), and
to keep the membrane in place on the liver, avoiding its
against CK19 (Clone-b170, dilution 1:100, Novocastra,dispersion into the peritoneal cavity. After this proce- Newcastle, UK) (45). Sections were again washed, anddure, the abdomen was closed, as described above for incubated with secondary antibody using the MACH 4TM
animals of the BDL group. After surgery, each rat was Universal HRP-polymer kit (Biocare Medical, Concord,given subcutaneous antibiotic therapy (Marbocyl 1%, 10 CA, USA) according to the manufacturer’s instructions.
mg/kg) and following the recommendations of Beck and For visualization, diaminobenzidine (BioGenex Labora-Lee (6), subcutaneous injection of vitamin K (5 mg/kg)
tories, San Remon, CA) was applied for 5 min. All sec-
was administered weekly to decrease mortality from
tions were counterstained with hematoxylin, dehydratedhemorrhagic diathesis. in alcohol, cleared in xylene, and mounted with Eukitt
Mounting MediumTM (Fluka Biochemika, Steinheim,
Liver Explants and Histological Processing Germany). Slides were then air dried. The specificity of
the antibody–antigen reaction was tested by replacingTwo, 4, and 6 weeks after BDL, 10 animals of each
group were euthanized with an excess of isoflurane. the primary antibodies with normal serum from the do-
nor species of the first antibody (mouse IgG2a, DakoLiver samples were taken from the major left and me-
dian lobes (which comprise approximately 70% of the Corporation, Denmark). As an internal control, vascular
smooth muscle and bile duct immunoreactivity were as-liver), fixed in 10% neutral buffered formalin (for at
least 48 h), and embedded in paraffin. At least four 4- sessed for α-SMA and CK19, respectively.
µm-thick sections were used from each rat and these
Image Morphometric Analysiswere stained with hematoxylin/eosin and with Goldner’s
modified Masson trichrome staining procedure for fibro- Goldner’s modified Masson trichrome staining, CK19
and α-SMA immunostainings were quantitatively evalu-sis and collagen analysis, or placed on polysine-L-coated
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ated by digital image analysis. The quantification was nation of rat liver tissues that had been subjected to Gold-
ner’s modified Masson trichrome staining. This methodperformed using the open-source CellProfiler image
analysis software (27). The images of all stainings were allows a staging of fibrotic and cirrhotic liver lesions,
by considering not only the extent of ECM depositioncaptured by a digital camera (Olympus Camedia C-4040
ZOOM) and digitalized at 1024 × 768 pixel, 24 bit/pixel (i.e., collagen deposition) but also the progressive
expansion of the lesions from portal regions to graduallyresolution with a global magnification of 100×. The dig-
ital images were processed by CellProfiler, to identify, involving the interstitial parenchyma, and finally result-
ing in liver remodeling.isolate, and measure areas occupied by immunostained
cells or by collagen deposition over the total liver paren- After BDL induction, the onset of the fibrotic injury
is mainly characterized by periductular collagen depositschyma area.
The mean value taken from 10 nonoverlapping ran- along the portal tracts (score 1). Subsequently, the fi-
brotic process infiltrates the hepatic parenchyma anddom fields per section, all of which contained the central
vein and the portal tracts, was used to generate a single forms bridging septa (linkage) between portal tracts and
between portal tracts and the central vein (score 3). Fi-value for each specimen.
nally, the liver architecture is severely compromised. A
Nomenclature to Designate Biliary Structures marked collagen accumulation is observed in the inter-
stitial spaces with formation of fibrous septa separatingThe terminology used in this work to designate bili-
ary structures refers to the consensus on nomenclature and surrounding small nodules of parenchyma: this de-
fines the cirrhosis stage (score 4). Representative photo-of the finer branches of the biliary tree published by
Roskams et al., and also applied by other authors to de- micrographs of each fibrosis score, obtained at different
times after the BDL procedure in the BDL rat group, arescribe “ductular reaction” and liver fibrosis after BDL
(5,21,42). “Ductular reaction” implies a reaction of duc- shown in Figure 1.
In both experimental groups (BDL and BDL + AM),tular phenotype. In the case of injury caused by obstruc-
tion of the common bile duct (BDL model), we will use liver fibrosis became detectable 2 weeks post-BDL pro-
cedure and was located around biliary structures of thethis term to designate the increasing numbers of biliary
structures (ductules) (i.e., cholangiocyte proliferation) portal tracts. Interestingly, although in the control BDL
group the fibrosis worsened progressively thereafter,that arise in response to the injury and that are intensely
CK19 positive. reaching the cirrhosis stage at the last time point, in
BDL + AM rats the progression of liver fibrosis was less
Statistical Analysis severe than that observed in BDL rats. Indeed, in BDL +
AM rats, fibrosis remained confined at the portal/peri-Data are reported as median and interquartile range
(IQR). Kruskal-Wallis nonparametric analysis of vari- portal areas, with no formation of complete fibrous sep-
tal linkage between portal tracts, no fibrotic process inance was performed to evaluate the statistical signifi-
cance of the difference among treatment groups. Differ- the interstitial spaces of hepatic parenchyma and, impor-
tantly, no cirrhotic lesions were ever observed.ences between treatment groups at the specific time
points were then assessed by using the Mann-Whitney Semiquantitative Knodell scoring of these experi-
mental results is reported in Figure 2. Specifically, at 4test with Holm-Bonferroni’s correction for multiple
comparisons. A value of p < 0.05 was considered statis- weeks post-BDL, the median score values were 2.0
(IQR: 2.0) in BDL + AM rats and 3.0 (IQR: 1.0) in BDLtically significant. Data analysis was performed with
SPSS for Windows, version 10.0 (SPSS Inc., Chicago, rats (p<0.05). In contrast with BDL rats, which showed
a continuous evolution of fibrosis from week 4 to weekIL, USA).
6 [from 3.0 (IQR: 1.0) to 4.0 (IQR: 1.0) score units],
RESULTS BDL + AM rats did not show any further fibrotic pro-
gression [the fibrosis median score value remained atThe potential role of human AM patches for the treat-
ment of liver fibrosis was investigated in rats subjected 2.0 (IQR: 2.0) at both time points].
Considering that liver fibrotic injury induced by theto the common BDL and scission procedures, a classical
experimental method to induce biliary fibrosis in animal BDL procedure is the outcome of a cascade of events
and that multiple profibrogenic pathways are activatedmodels and to analyze the events leading from the initial
injury of the bile ducts to the organization of a fibrotic in this process, as well as undertaking the semiquantita-
tive evaluation of the fibrotic process, we included inreaction, and, finally, to the outcome of cirrhosis (21).
The level of fibrosis achieved was firstly assessed by our study, as reported below, the quantitative assessment
of three main parameters that are specifically involvedthe classical semiquantitative Knodell fibrosis scoring
system (7), which was applied to the histological exami- in the establishment and progression of such a biliary
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Figure 1. Sample pictures of semiquantitative Knodell scoring patterns for liver fibrosis. (A) Rat liver, score 0: the periportal area
is morphologically normal and characterized by the presence of a thin rim of light green stained collagen (arrow). (B) Rat liver,
score 1: portal tract is enlarged by the accumulation of periductular intensely green-stained collagen deposits (arrow). (C) Rat liver,
score 3: collagen infiltration forms bridging septa between portal tracts (arrow). (D) Rat liver, score 4: collagen deposition infiltrates
lobular parenchyma (arrow). Samples in (A–D): Goldner’s modified Masson trichrome staining. Scale bar: 100 µm.
fibrotic lesion: ductular reaction, myofibroblast activa- ous bile ductules in the periportal areas (Fig. 3A). Four
weeks after BDL, the ductular reaction continued in thetion, and collagen deposition.
portal/periportal areas and extended deeply into the he-
Human AM Reduced BDL-Induced Ductular Reaction patic lobule (Fig. 3B). At week 6, the ductular reaction
was very intense and delineated complete nodules of he-To evaluate the potential of human AM in reducing
the ductular reaction (i.e., the abnormal proliferation of patic parenchyma, with additional CK19-positive small
ductules arising within these circumscribed nodulesbiliary structures) induced by the BDL procedure, we
analyzed the expression of CK19, a marker of biliary (Fig. 3C).
In BDL + AM rats, although the ductular reaction ob-epithelial cells, in the liver tissues of BDL and BDL +
AM group rats. served at week 2 was similar to that found in BDL rats,
at the later time points it progressed more slowly thanIn the liver tissues of the BDL group, the ductular
reaction progressively and constantly increased from in BDL rats (Fig. 3D–F). Intriguingly, at week 6, in
contrast to the BDL group, the ductular reaction did notweek 2 up to week 6, as can be seen from representative
photomicrographs, captured at different time points (Fig. circumscribe any nodules of hepatic parenchyma (Fig. 3F).
The areas occupied by CK19-positive cells were3A–C). Specifically, at week 2, well-formed biliary
structures were observed in the portal tracts and numer- quantitatively evaluated by digital image analysis (Fig.
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Figure 2. Semiquantitative Knodell scoring of experimental groups. Median with IQR range of 10
independent experiments is represented as boxplots for BDL (dark gray) and BDL + AM (light
gray) groups, at each different time point. Dotted lines between boxplots represent the trend of
median differences in BDL (dark gray) and BDL + AM (light gray) groups. Curly brackets repre-
sent significant difference between groups at the same time point. Lines at the base of boxplots
represent significant difference between time points in BDL (dark gray) and BDL + AM (light
gray) groups. *p < 0.05; **p < 0.01.
3G–I). At week 2, in BDL rats CK19-positive cells oc- terminal hepatic venules, whereas the bile ducts are α-
SMA negative (5).cupied 5.36% (IQR: 3.40) of the total liver area (Fig.
3I). Subsequently, the area occupied by CK19-positive In BDL rats, a progressive increase in α-SMA immu-
noreactivity was found at all time points analyzed, andcells progressively increases. Indeed, at week 4, this oc-
cupied 12.76% (IQR: 7.53) of the liver area (Fig. 3I) this colocalized with fibrosis (collagen deposition)
around biliary structures. At week 2, α-SMA-positiveand at week 6 the hepatic parenchyma area involved was
almost doubled to 18.82% (IQR: 9.75) (Fig. 3I). cells were found mainly in portal tracts (Fig. 4A). After-
wards, at week 4, α-SMA-positive cells surrounded theIn BDL + AM rats at week 4, only 5.91% (IQR: 5.05)
of the liver area was involved in ductular reaction (p < reactive bile ductules that formed portal–portal bridges
during the progression of fibrosis (Fig. 4B) and at week0.01 vs. BDL group, at the same time point) (Fig. 3I),
and at week 6 it only weakly increased up to 9.45% 6, α-SMA immunoreactivity was also detected around
ductules going deeply into the hepatic lobule and into(IQR: 3.85) (p < 0.01 vs. BDL group) (Fig. 3I).
perisinusoidal spaces (Fig. 4C).
Human AM Reduced BDL-Induced α-SMA immunoreactivity detected in rats treated
Myofibroblast Activation with human AM was lower at all time points with re-
spect to that found in BDL rats. In these rats, α-SMA-Given that α-SMA-positive and therefore activated
myofibroblasts are the principal cells responsible for the positive cells were found in the portal and periportal ar-
eas and, even at week 6, they were confined to thesecollagen production and deposition observed in the fi-
brosis process (58), we assessed the potential of human areas without homogenous distribution around all biliary
structures (i.e., not all periductular cells were immuno-AM to reduce myofibroblast activation by monitoring
the presence of α-SMA-positive cells in liver samples positive) (Fig. 4D–F).
The data obtained by the quantitative digital imagecollected from rats of both experimental groups at dif-
ferent time points after BDL induction. analysis confirmed a lower presence of activated myofi-
broblasts in the livers of AM-treated rats with respect toIn normal liver, α-SMA immunoreactivity is re-
stricted to the wall of portal veins, hepatic arterioles, and BDL rats (Fig. 4G–I). Indeed, at week 2, the liver area
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Figure 3. Quantitative evaluation of CK19 immunohistochemical staining in experimental groups. (A–C) Rat liver, BDL group:
representative microphotographs at 2, 4, and 6 weeks, respectively. (D–F) Rat liver, BDL + AM group: representative microphoto-
graphs at 2, 4, and 6 weeks, respectively. (G) Sample microphotograph taken before the image analysis procedure used to extrapo-
late the CK19 staining from the image. (H) Sample image, same as in (G), representing a step of the image analysis procedure
used: white areas are representative of CK19 staining. (I) Values of quantitative CK19 scoring in different groups: median with
IQR range of 10 independent experiments is represented as boxplots for BDL (dark gray) and BDL + AM (light gray) groups, at
each different time point. Dotted lines between boxplots represent the trend of median differences in BDL (dark gray) and BDL +
AM (light gray) groups. Curly brackets represent significant difference between groups at the same time point. Lines at the bottom
of boxplots represent significant difference between time points in BDL (dark gray) and BDL + AM (light gray) groups. *p < 0.05;
**p < 0.01. Samples in (A–G) were stained using indirect immunoperoxidase method with hematoxylin counterstaining. Scale bar:
100 µm.
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Figure 4. Quantitative evaluation of α-SMA immunohistochemical staining in experimental groups. (A–C) Rat liver, BDL group:
representative microphotographs at 2, 4, and 6 weeks, respectively. (D–F) Rat liver, BDL + AM group: representative microphoto-
graphs at 2, 4, and 6 weeks, respectively. (G) Sample microphotograph taken before the image analysis procedure used to extrapo-
late the α-SMA staining from the image. (H) Sample image, same as in (G), representing a step of the image analysis procedure
used: white areas are representative of α-SMA staining. (I) Values of quantitative α-SMA scoring in different groups: Median with
IQR range of 10 independent experiments is represented as boxplots for BDL (dark gray) and BDL + AM (light gray) groups, at
each different time point. Dotted lines between boxplots represent the trend of median differences in BDL (dark gray) and BDL +
AM (light gray) groups. Curly brackets represent significant difference between groups at the same time point. Lines at the bottom
of boxplots represent significant difference between time points in BDL (dark gray) and BDL + AM (light gray) groups. *p < 0.05;
**p < 0.01. Samples in (A–G) were stained using indirect immunoperoxidase method with hematoxylin counterstaining. Scale bar:
100 µm.
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occupied by α-SMA-positive cells in the AM-treated AM could serve as a hepatoprotective agent against he-
patic damage associated with fibrotic degeneration.rats was only 4.90% (IQR: 4.62) while in BDL rats it
was 9.11% (IQR: 3.39) (p < 0.01 vs. BDL group at the Biliary fibrosis and resultant cirrhosis are among the
most common outcomes of chronic liver diseases. Un-same time point) (Fig. 4I). At week 4, α-SMA-positive
cells occupied 9.63% of the liver area (IQR: 7.72) in fortunately, the therapeutic repertoire currently available
for treating liver fibrosis and cirrhosis of this type andBDL + AM rats (p < 0.05 vs. BDL group) and 14.87%
(IQR: 6.92) in BDL rats (Fig. 4I). Intriguingly, at week others is very limited and, often, the only effective re-
maining treatment is orthotopic liver transplantation6, while in BDL group the liver area occupied by the
activated myofibroblasts increased to 21.85% (IQR: (1,36). Therefore, strategies to reduce hepatic fibrosis
and to avoid the need for organ transplantation are11.10) (Fig. 4I), in the AM-treated rats it was 4.76%
(IQR: 3.10) (p < 0.01 vs. BDL group), an area even strongly required. To our knowledge, this is the first
study aiming at investigating whether human AMsmaller than that occupied at week 4 and similar to that
occupied at week 2 (Fig. 4I). patches can be used as a possible treatment for biliary
fibrosis in an animal model (BDL-treated rat) commonly
Human AM Decreased the BDL-Induced used for the study of such a type of fibrosis, and that
Collagen Deposition mimics very well the situation of extrahepatic cholesta-
sis arising in a variety of human liver diseases (21,To quantitatively evaluate the effects of human AM
on liver collagen deposition, Goldner’s modified Mas- 30,40).
First, we have demonstrated that human AM applica-son trichrome staining-positive areas were analyzed and
quantified by image analysis morphometry in liver sam- tion reduces liver fibrosis when evaluated using the clas-
sical semiquantitative Knodell scoring system. Indeed,ples collected from rats of both experimental groups.
Representative photomicrographs and quantitative data while in the BDL rat group, fibrosis showed a rapid pro-
gression leading to cirrhosis within 6 weeks, with colla-collected after 2, 4, and 6 weeks from BDL and BDL +
AM rats are shown in Figure 5. gen accumulation around ductular structures and in the
interstitial spaces, in the BDL + AM rat group the appli-In BDL rats, from week 2 to week 4, liver collagen
deposition markedly increased and no further significant cation of human AM was able to confine the fibrosis to
the portal/periportal area, with no formation of completeexpansion of occupied liver area was observed after
week 4 (Fig. 5A–C). Furthermore, although collagen de- fibrous septal linkage between portal tracts and no fur-
ther progression in liver fibrosis after 4 weeks fromposition observed at week 2 was similar in the two
group of animals, afterwards no further progression was BDL.
By conducting an in-depth analysis of the stages thatobserved in the BDL + AM rats (Fig. 5D–F).
The quantitative evaluation by digital image analysis characterize biliary fibrosis induced by the BDL proce-
dure, our results indicate that the application of humanconfirmed that, at week 2, collagen deposition was com-
parable in rats of both groups (Fig. 5G–I) but subse- AM inhibits the cascade of events leading to liver fibro-
sis/cirrhosis in such a model, resulting in a final reduc-quently it was significantly reduced in the AM-treated
rats. Indeed, in BDL rats at week 4, the collagen deposi- tion of hepatic fibrosis.
Specifically, we have shown that the application oftion area involved 20.61% (IQR: 6.78) of the liver area
(Fig. 5I) and at week 6, it remained at 18.38% (IQR: human AM slows the gradual progression of the ductu-
lar reaction, to the point that it is significantly reduced8.29) (Fig. 5I). In contrast, in BDL + AM rats, liver ar-
eas occupied by collagen at week 4 and week 6 were within 6 weeks in BDL + AM rats compared to the BDL
rat group. This is a very important finding, consideringonly 9.92% (IQR: 2.15) and 11.35% (IQR: 1.54), re-
spectively (p < 0.01 vs. BDL group at the same time that the ductular reaction (i.e., cholangiocyte prolifera-
tion and increased number of ductules) is one of the firstpoints) (Fig. 5I).
process triggered by the BDL procedure and is thought
DISCUSSION to have a key role in the initiation and progression of
liver fibrosis (13,21,41). These results are in line withThis study demonstrates that human AM, when ap-
plied as a patch onto the liver surface, reduces progres- those reported by Chen et al. (10). Indeed, these authors,
using the BDL model to induce liver fibrosis, demon-sion of experimental biliary fibrosis induced in rats by
the BDL procedure. Combining a semiquantitative eval- strated that chromium attenuation of liver fibrosis was
first evidenced by a reduction in the severity of BDL-uation of the fibrotic process and the quantitative assess-
ment of three main parameters specifically involved in induced ductular reaction.
Following ductular proliferation, the chronic obstruc-the establishment and progression of biliary fibrosis
(i.e., ductular reaction, myofibroblast activation, and tion of bile duct causes massive activation of myofi-
broblasts in the periductal region and at the end resultscollagen deposition), our findings suggest that human
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Figure 5. Quantitative evaluation of collagen histochemical staining in experimental groups. (A–C) Rat liver, BDL group: represen-
tative microphotographs at 2, 4, and 6 weeks, respectively. (D–F) Rat liver, BDL + AM group: representative microphotographs at
2, 4, and 6 weeks, respectively. (G) Sample microphotograph taken before the image analysis procedure used to extrapolate the
collagen staining from the image. (H) Sample image, same as in (G), representing a step of the image analysis procedure used:
white areas are representative of green collagen staining. (I) Values of quantitative collagen deposition in different groups: Median
with IQR range of 10 independent experiments is represented as boxplots for BDL (dark gray) and BDL + AM (light gray) groups,
at each different time point. Dotted lines between boxplots represent the trend of median differences in BDL (dark gray) and BDL
+ AM (light gray) groups. Curly brackets represent significant difference between groups at the same time point. Lines at the
bottom of boxplots represent significant difference between time points in BDL (dark gray) and BDL + AM (light gray) groups.
*p < 0.05; **p < 0.01. Samples in (A–G) were stained using Goldner’s modified Masson trichrome staining procedure. Scale bar:
100 µm.
AMNIOTIC MEMBRANE REDUCES LIVER FIBROSIS 451
in biliary fibrosis/cirrhosis (3,59). From this study we also been hypothesized by Tsai et al. (55) to explain the
observed reduction in liver fibrosis in the absence offound that human AM reduces the occurrence of α-
SMA-expressing cells in the hepatic parenchyma after differentiation of engrafted Wharton’s jelly-derived
cells, which had been transplanted into rats with carbonBDL induction, and this was already evident 2 weeks
after BDL. α-SMA is the histological hallmark of acti- tetrachloride (CCl4)-induced liver fibrosis. In addition,
we have recently hypothesized such a paracrine mecha-vated myofibroblasts, which secrete large amounts of
ECM proteins, including collagen, and increase ECM nism to explain the ability of placenta-derived cells to
reduce bleomycin-induced lung fibrosis (9) and of hu-accumulation during fibrosis (58). Given that, in biliary
fibrosis induced by BDL, α-SMA-positive myofi- man AM patches to exert a protective effect against is-
chemia-induced changes in cardiac functions and dimen-broblasts may originate not only from hepatic stellate
cells (HSCs)/residential fibroblasts, but also from the sions (8). This hypothesis stems from the fact that the
AM, as well as cells derived from this tissue, are ablebile duct epithelium through epithelial–mesenchymal
transition (EMT) (21,59), the reduction in the area occu- to release several factors that have potent immunomodu-
latory, anti-inflammatory, and antiscarring effects (12,50).pied by myofibroblasts could be correlated, at least in
part, with the decreased ductular reaction area observed Nevertheless, the identification of the specific para-
crine bioactive molecules produced by AM and their tar-in the rat group treated with AM.
Finally, our data suggest that the reduction in ductu- get cells involved in the antifibrotic effects of AM on
the liver remains to be explored. Considering that sev-lar proliferation and in myofibroblast activation could
participate in the attenuation of the collagen deposition eral studies have suggested that proliferating cholangio-
cytes have a role in the induction of liver biliary fibrosis,process. Although at 2 weeks after BDL the collagen
deposition area was not significantly different in BDL + either directly, via EMT and therefore providing a source
of fibrogenic myofibroblasts, or indirectly via activationAM rats compared to the BDL rats, after 4 and 6 weeks,
collagen deposition was reduced by about 50% in the of other liver cell types, such as resident portal fibro-
blasts and HSCs (21), by means of autocrine and para-BDL + AM rats group. These data indicate a novel strat-
egy for reducing collagen deposition in a BDL model of crine mediators, (21,26,59), it is conceivable that one of
the targets of the paracrine actions of human AM mightbiliary fibrosis. Indeed, other studies reported to date
using this same experimental model have demonstrated be cholangiocytes. Furthermore, taking into account the
fact that the AM can modulate TGF-β1 synthesis and/orreduction of hepatic collagen deposition by means of
other therapeutic agents, such as chromium supplemen- signaling pathways (29,47,56), it is possible that the hu-
man AM patch might lead to a reduction in the expres-tation (10) and hepatocyte growth factor (14,59).
Taken together, these data indicate that the human sion of profibrogenic factors such as TGF-β1 and
PDGF, or proinflammatory cytokines (e.g., IL-1, IL-6,AM does not prevent the formation of fibrosis, but cer-
tainly inhibits its progression to the end stage of disease. etc.). To perform an exhaustive assessment of fibrosis
and avoid potential confusing findings deriving from in-The exact mechanism whereby human AM exerts
these beneficial effects on BDL-induced liver fibrosis complete sampling, our approach called for whole organ
resection and formalin fixation, which prevented usremains to be defined, and at present we can only specu-
late as to the nature of such mechanisms. Because by in from performing expression studies in the livers of our
experimental animals. However, it is worth noting thatsitu hybridization analysis (for human genome-specific
ALU-repetitive DNA sequences and human chromo- reduction of TGF-β1 expression has been previously
suggested to explain part of the mechanism of fibrosissome 17 centromere) (data not shown) no human cells
were detected in the sections of AM-treated rat livers, reduction achieved by other approaches, such as MSC
transplantation (25,55), HGF administration (59), andthis suggests that, within the limits of these experimental
methods, no massive (or at least very low/undetectable) chromium supplementation (10).
Nonetheless, direct testing of the potential paracrineengraftment of AM-derived cells occurred in the host
liver. Although we cannot exclude the possibility that function of the AM, as well as of other cell types that
have been shown to have anti-inflammatory and antifi-few AM-derived cells engrafted in the liver, it is con-
ceivable that the beneficial effects exerted by AM patch brotic effects (11,55), would add mechanistic insights to
our findings and clearly warrants further experimenta-application might not be due to a replacement mecha-
nism, in which engrafted AM-derived cells differenti- tions.
Because the same therapeutic approach may exertated toward the hepatogenic lineage, but that, most
likely, the effects observed were associated with the re- different, and even opposite, effects (reduction versus
worsening) on fibrogenesis according to the type of fi-lease of soluble factors by cells of the human AM patch
(and of the few engrafted cells), which exerted paracrine brosis/cirrhosis (57), the beneficial effects achieved with
the human AM patch on BDL-induced biliary fibrosiseffects. This mechanism, based on paracrine effects, has
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